{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:21:56Z","timestamp":1787163716714,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2016-00906"],"award-info":[{"award-number":["2016-00906"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["2017-0383"],"award-info":[{"award-number":["2017-0383"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011898","name":"Marcus och Amalia Wallenbergs minnesfond","doi-asserted-by":"publisher","award":["2015.0125"],"award-info":[{"award-number":["2015.0125"]}],"id":[{"id":"10.13039\/501100011898","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Strategic Research Area MultiPark"},{"name":"Swedish Alzheimer Foundation","award":["AF-939932"],"award-info":[{"award-number":["AF-939932"]}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"crossref","award":["FO2021-0293"],"award-info":[{"award-number":["FO2021-0293"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Parkinson foundation of Sweden","award":["1280\/20"],"award-info":[{"award-number":["1280\/20"]}]},{"DOI":"10.13039\/501100006129","name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sk\u00e5ne University Hospital Foundation","award":["2020-O000028"],"award-info":[{"award-number":["2020-O000028"]}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To examine [\n                      <jats:sup>18<\/jats:sup>\n                      F]RO948 retention in FTD, sampling the underlying protein pathology heterogeneity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 61 individuals with FTD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200935), matched cases of AD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200913) and A\u03b2-negative cognitively unimpaired individuals (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200913) underwent [\n                      <jats:sup>18<\/jats:sup>\n                      F]RO948PET and MRI. FTD included 21 behavioral variant FTD (bvFTD) cases, 11 symptomatic\n                      <jats:italic>C9orf72<\/jats:italic>\n                      mutation carriers, one patient with non-genetic bvFTD-ALS, one individual with bvFTD due to a\n                      <jats:italic>GRN<\/jats:italic>\n                      mutation, and one due to a\n                      <jats:italic>MAPT<\/jats:italic>\n                      mutation (R406W). Tracer retention was examined using a region-of-interest and voxel-wise approaches. Two individuals (bvFTD due to\n                      <jats:italic>C9orf72<\/jats:italic>\n                      ) underwent postmortem neuropathological examination. Tracer binding was additionally assessed in vitro using [\n                      <jats:sup>3<\/jats:sup>\n                      H]RO948 autoradiography in six separate cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]RO948 retention across ROIs was clearly lower than in AD and comparable to that in A\u03b2-negative cognitively unimpaired individuals. Only minor loci of tracer retention were seen in bvFTD; these did not overlap with the observed cortical atrophy in the cases, the expected pattern of atrophy, nor the expected or verified protein pathology distribution. Autoradiography analyses showed no specific [\n                      <jats:sup>3<\/jats:sup>\n                      H]RO948 binding. The R406W\n                      <jats:italic>MAPT<\/jats:italic>\n                      mutation carriers were clear exceptions with AD-like retention levels and specific in-vitro binding.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]RO948 uptake is not significantly increased in the majority of FTD patients, with a clear exception being specific\n                      <jats:italic>MAPT<\/jats:italic>\n                      mutations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-022-06065-4","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T23:33:53Z","timestamp":1670974433000},"page":"1371-1383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["[18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes"],"prefix":"10.1007","volume":"50","author":[{"given":"Alexander F.","family":"Santillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Leuzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Honer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Landqvist Wald\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Tideman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Ohlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"J\u00f6gi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"van Swieten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"6065_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954\u201363. https:\/\/doi.org\/10.1038\/s41591-021-01382-x.","journal-title":"Nat Med"},{"key":"6065_CR2","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L, et al. Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge. Mol Psychiatry. 2019;24:1112\u201334. https:\/\/doi.org\/10.1038\/s41380-018-0342-8.","journal-title":"Mol Psychiatry"},{"key":"6065_CR3","unstructured":"Federal Drug Administration. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-image-tau-pathology-patients-being-evaluated-alzheimers-disease.. Accessed 25 Mar 2022."},{"key":"6065_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/bpa.12486","volume":"27","author":"DMA Mann","year":"2017","unstructured":"Mann DMA, Snowden JS. Frontotemporal lobar degeneration: pathogenesis, pathology and pathways to phenotype. Brain Pathol. 2017;27:723\u201336. https:\/\/doi.org\/10.1111\/bpa.12486.","journal-title":"Brain Pathol"},{"issue":"Suppl 1","key":"6065_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/jnc.13588","volume":"138","author":"IRA Mackenzie","year":"2016","unstructured":"Mackenzie IRA, Neumann M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J Neurochem. 2016;138(Suppl 1):54\u201370. https:\/\/doi.org\/10.1111\/jnc.13588.","journal-title":"J Neurochem"},{"key":"6065_CR6","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ana.24885","volume":"81","author":"EG Spinelli","year":"2017","unstructured":"Spinelli EG, Mandelli ML, Miller ZA, et al. Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol. 2017;81:430\u201343.","journal-title":"Ann Neurol"},{"key":"6065_CR7","doi-asserted-by":"publisher","unstructured":"Ahmed RM, Bocchetta M, Todd EG, et al. Tackling clinical heterogeneity across the amyotrophic lateral sclerosis-frontotemporal dementia spectrum using a transdiagnostic approach. Brain Commun. 2021;3(4):fcab257. Published 2021 Oct 23. https:\/\/doi.org\/10.1093\/braincomms\/fcab257.","DOI":"10.1093\/braincomms\/fcab257."},{"key":"6065_CR8","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1093\/brain\/awx254","volume":"140","author":"DC Perry","year":"2017","unstructured":"Perry DC, Brown JA, Possin KL, et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain. 2017;140:3329\u201345. https:\/\/doi.org\/10.1093\/brain\/awx254.","journal-title":"Brain"},{"issue":"1","key":"6065_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00401-016-1650-1","volume":"133","author":"R Smith","year":"2017","unstructured":"Smith R, Sch\u00f6ll M, Honer M, et al. Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. Acta Neuropathol. 2017;133(1):149\u201351. https:\/\/doi.org\/10.1007\/s00401-016-1650-1.","journal-title":"Acta Neuropathol"},{"key":"6065_CR10","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1136\/jnnp-2017-316402","volume":"89","author":"WR Bevan-Jones","year":"2018","unstructured":"Bevan-Jones WR, Cope TE, Jones PS, et al. [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurology Neurosurg Psychiatry. 2018;89:1032\u20137. https:\/\/doi.org\/10.1136\/jnnp-2017-316402.","journal-title":"J Neurology Neurosurg Psychiatry"},{"key":"6065_CR11","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/acn3.631","volume":"5","author":"RW Bevan-Jones","year":"2018","unstructured":"Bevan-Jones RW, Cope TE, Jones SP, et al. [ 18 F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion. Ann Clin Transl Neurol. 2018;5:1292\u20136. https:\/\/doi.org\/10.1002\/acn3.631.","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"6065_CR12","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/jnnp-2017-316409","volume":"89","author":"SJ Makaretz","year":"2018","unstructured":"Makaretz SJ, Quimby M, Collins J, et al. Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2018;89(10):1024\u201331. https:\/\/doi.org\/10.1136\/jnnp-2017-316409.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6065_CR13","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1038\/s41598-019-42625-9","volume":"9","author":"R Smith","year":"2019","unstructured":"Smith R, Santillo AF, Landqvist Wald\u00f6 M, et al. 18F-Flortaucipir in TDP-43\u2013associated frontotemporal dementia. Sci Rep. 2019;9:6082. https:\/\/doi.org\/10.1038\/s41598-019-42625-9.","journal-title":"Sci Rep"},{"key":"6065_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-019-0470-7","volume":"11","author":"RM Tsai","year":"2019","unstructured":"Tsai RM, Bejanin A, Lesman-Segev O, et al. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alz Res Therapy. 2019;11:13. https:\/\/doi.org\/10.1186\/s13195-019-0470-7.","journal-title":"Alz Res Therapy"},{"issue":"8","key":"6065_CR15","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy A, Smith R, Ossenkoppele R, et al. Diagnostic performance of [18F]RO948 tau positron emission tomography in the differentiation of AD from other neurodegenerative disorders. JAMA Neurol. 2020;77(8):955\u201365. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0989.","journal-title":"JAMA Neurol"},{"key":"6065_CR16","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456\u201377. https:\/\/doi.org\/10.1093\/brain\/awr179.","journal-title":"Brain"},{"key":"6065_CR17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006\u201314. https:\/\/doi.org\/10.1212\/WNL.0b013e31821103e6.","journal-title":"Neurology"},{"key":"6065_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183\u201394. https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01388.x.","journal-title":"J Intern Med"},{"key":"6065_CR19","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5). Arlington, VA; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"6065_CR20","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan RS, S\u00e9gonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral-based regions of interest. Neuroimage. 2006;31:968\u201380. https:\/\/doi.org\/10.1016\/j.neuroimage.2006.01.021.","journal-title":"Neuroimage"},{"issue":"5","key":"6065_CR21","first-page":"904","volume":"39","author":"OG Rousset","year":"1998","unstructured":"Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904\u201311.","journal-title":"J Nucl Med"},{"key":"6065_CR22","doi-asserted-by":"publisher","unstructured":"Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer\u2019s disease vs. other neurodegenerative disorders. JAMA. 2018;320:1151\u20131162. https:\/\/doi.org\/10.1001\/jama.2018.12917.","DOI":"10.1001\/jama.2018.12917."},{"key":"6065_CR23","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00259-020-05099-w","volume":"48","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Leuzy A, Cho H, et al. The impact of demographic, clinical, genetic, and imaging variables on tau PET status. Eur J Nucl Med Mol Imaging. 2021;48:2245\u201358. https:\/\/doi.org\/10.1007\/s00259-020-05099-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6065_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer\u2019s disease. Ann Neurol. 2016;79:110\u20139. https:\/\/doi.org\/10.1002\/ana.24546.","journal-title":"Ann Neurol"},{"key":"6065_CR25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Sch\u00f6ll","year":"2016","unstructured":"Sch\u00f6ll M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89:971\u201382. https:\/\/doi.org\/10.1016\/j.neuron.2016.01.028.","journal-title":"Neuron"},{"key":"6065_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1474-4422(17)30077-7","volume":"16","author":"CR Jack","year":"2017","unstructured":"Jack CR, Wiste HJ, WeigandS D, et al. Age-specific and sex-specific prevalence of cerebral \u03b2-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50\u201395 years: a cross-sectional study. Lancet Neurol. 2017;16:435\u201344. https:\/\/doi.org\/10.1016\/S1474-4422(17)30077-7.","journal-title":"Lancet Neurol"},{"issue":"6","key":"6065_CR27","doi-asserted-by":"publisher","first-page":"944","DOI":"10.2967\/jnumed.117.200006","volume":"59","author":"S Southekal","year":"2018","unstructured":"Southekal S, Devous MD Sr, Kennedy I, et al. Flortaucipir F 18 quantitation using parametric estimation of reference signal intensity. J Nucl Med. 2018;59(6):944\u201351. https:\/\/doi.org\/10.2967\/jnumed.117.200006.","journal-title":"J Nucl Med"},{"key":"6065_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/2051-5960-2-70","volume":"2","author":"YS Davidson","year":"2014","unstructured":"Davidson YS, Barker H, Robinson AC, et al. Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun. 2014;2:70. https:\/\/doi.org\/10.1186\/2051-5960-2-70.","journal-title":"Acta Neuropathol Commun"},{"key":"6065_CR29","doi-asserted-by":"publisher","first-page":"9661","DOI":"10.1523\/JNEUROSCI.2160-09.2009","volume":"29","author":"J Whitwell","year":"2009","unstructured":"Whitwell J. Voxel-based morphometry: an automated technique for assessing structural changes in the brain. J Neurosci. 2009;29:9661\u20134. https:\/\/doi.org\/10.1523\/JNEUROSCI.2160-09.2009.","journal-title":"J Neurosci"},{"key":"6065_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.neuroimage.2007.07.007","volume":"38","author":"J Ashburner","year":"2007","unstructured":"Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38:95\u2013113. https:\/\/doi.org\/10.1016\/j.neuroimage.2007.07.007.","journal-title":"Neuroimage"},{"key":"6065_CR31","doi-asserted-by":"publisher","first-page":"16265","DOI":"10.1523\/JNEUROSCI.2170-12.2012","volume":"32","author":"R La Joie","year":"2012","unstructured":"La Joie R, Perrotin A, Barr\u00e9 L, et al. Region-specific hierarchy between atrophy, hypometabolism, and \u03b2-amyloid (A\u03b2) load in Alzheimer\u2019s disease dementia. J Neurosci. 2012;32:16265\u201373. https:\/\/doi.org\/10.1523\/JNEUROSCI.2170-12.2012.","journal-title":"J Neurosci"},{"key":"6065_CR32","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/brain\/awaa276","volume":"143","author":"DN Soleimani-Meigooni","year":"2020","unstructured":"Soleimani-Meigooni DN, Iaccarino L, La Joie R, et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer\u2019s disease and other neurodegenerative diseases. Brain. 2020;143:3477\u201394. https:\/\/doi.org\/10.1093\/brain\/awaa276.","journal-title":"Brain"},{"key":"6065_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"BR Brooks","year":"2000","unstructured":"Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293\u20139. https:\/\/doi.org\/10.1080\/146608200300079536.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"Pt 3","key":"6065_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/brain\/awr354","volume":"135","author":"GY Hsiung","year":"2012","unstructured":"Hsiung GY, DeJesus-Hernandez M, Feldman HH, et al. Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. Brain. 2012;135(Pt 3):709\u201322. https:\/\/doi.org\/10.1093\/brain\/awr354.","journal-title":"Brain"},{"issue":"1","key":"6065_CR35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/2051-5960-1-68","volume":"14","author":"DM Mann","year":"2013","unstructured":"Mann DM, Rollinson S, Robinson A, et al. Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun. 2013;14(1):68. https:\/\/doi.org\/10.1186\/2051-5960-1-68.","journal-title":"Acta Neuropathol Commun"},{"key":"6065_CR36","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00401-011-0907-y","volume":"122","author":"ME Murray","year":"2011","unstructured":"Murray ME, DeJesus-Hernandez M, Rutherford NJ, et al. Clinical and neuropathologic heterogeneity of c9FTD\/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol. 2011;122:673\u201390. https:\/\/doi.org\/10.1007\/s00401-011-0907-y.","journal-title":"Acta Neuropathol"},{"key":"6065_CR37","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/brain\/awr361","volume":"135","author":"CJ Mahoney","year":"2012","unstructured":"Mahoney CJ, Beck J, Rohrer JD, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical, and neuropathological features. Brain. 2012;135:736\u201350. https:\/\/doi.org\/10.1093\/brain\/awr361.","journal-title":"Brain"},{"issue":"7","key":"6065_CR38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher AS, Pontecorvo MJ, Devous MD Sr, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer\u2019s disease neuropathologic changes. JAMA Neurol. 2020;77(7):829\u201339.","journal-title":"JAMA Neurol"},{"key":"6065_CR39","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.1021\/acs.jmedchem.7b00632","volume":"60","author":"LC Gobbi","year":"2017","unstructured":"Gobbi LC, Knust H, K\u00f6rner M, et al. Identification of three novel radiotracers for imaging-aggregated tau in Alzheimer\u2019s disease with positron emission tomography. J Med Chem. 2017;60:7350\u201370. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00632.","journal-title":"J Med Chem"},{"key":"6065_CR40","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2967\/jnumed.117.196741","volume":"59","author":"M Honer","year":"2018","unstructured":"Honer M, Gobbi L, Knust H, et al. Preclinical evaluation of 18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 as novel PET radiotracers for imaging tau aggregates in Alzheimer\u2019s disease. J Nucl Med. 2018;59:675\u201381. https:\/\/doi.org\/10.2967\/jnumed.117.196741.","journal-title":"J Nucl Med"},{"key":"6065_CR41","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","volume":"12","author":"K Sander","year":"2016","unstructured":"Sander K, Lashley T, Gami P, et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer\u2019s disease, primary tauopathies, and other dementias. Alzheimer\u2019s Dement. 2016;12:1116\u201324. https:\/\/doi.org\/10.1016\/j.jalz.2016.01.003.","journal-title":"Alzheimer\u2019s Dement"},{"key":"6065_CR42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.neurobiolaging.2017.10.008","volume":"62","author":"DM Cash","year":"2018","unstructured":"Cash DM, Bocchetta M, Thomas DL, et al. Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiol Aging. 2018;62:191\u20136. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.10.008.","journal-title":"Neurobiol Aging"},{"key":"6065_CR43","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/brain\/awl271","volume":"12","author":"IR Mackenzie","year":"2006","unstructured":"Mackenzie IR, Baker M, Pickering-Brown S, et al. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain. 2006;12:3081\u201390. https:\/\/doi.org\/10.1093\/brain\/awl271.","journal-title":"Brain"},{"key":"6065_CR44","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ana.25183","volume":"83","author":"KA Josephs","year":"2018","unstructured":"Josephs KA, Martin PR, Botha H, et al. [18 F]AV-1451 tau-PET and primary progressive aphasia. Ann Neurol. 2018;83:599\u2013611. https:\/\/doi.org\/10.1002\/ana.25183.","journal-title":"Ann Neurol"},{"key":"6065_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/WAD.0000000000000216","volume":"32","author":"H Lee","year":"2018","unstructured":"Lee H, Seo S, Lee SY, et al. [18F]-THK5351 PET imaging in patients with semantic variant primary progressive aphasia. Alzheimer Dis Assoc Disord. 2018;32:62\u20139. https:\/\/doi.org\/10.1097\/WAD.0000000000000216.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"6065_CR46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00401-018-1951-7","volume":"137","author":"KA Josephs","year":"2019","unstructured":"Josephs KA, Murray ME, Tosakulwong N, et al. Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathol. 2019;137(2):227\u201338. https:\/\/doi.org\/10.1007\/s00401-018-1951-7.","journal-title":"Acta Neuropathol"},{"key":"6065_CR47","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503\u201327. https:\/\/doi.org\/10.1093\/brain\/awz099.","journal-title":"Brain"},{"key":"6065_CR48","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-017-0330-2","volume":"10","author":"E Ygland","year":"2018","unstructured":"Ygland E, van Westen D, Englund E, et al. Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review. Alz Res Therapy. 2018;10:2. https:\/\/doi.org\/10.1186\/s13195-017-0330-2.","journal-title":"Alz Res Therapy"},{"issue":"Pt 9","key":"6065_CR49","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1093\/brain\/aww163","volume":"139","author":"R Smith","year":"2016","unstructured":"Smith R, Puschmann A, Sch\u00f6ll M, et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain. 2016;139(Pt 9):2372\u20139. https:\/\/doi.org\/10.1093\/brain\/aww163.","journal-title":"Brain"},{"key":"6065_CR50","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/jnnp-2013-306948","volume":"85","author":"L Chare","year":"2014","unstructured":"Chare L, Hodges JR, Leyton CE, et al. New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. J Neurol Neurosurg Psychiatry. 2014;85:865\u201370.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"66","key":"6065_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1212\/01.wnl.0000191307.69661.c3","volume":"10","author":"KA Josephs","year":"2006","unstructured":"Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006;10(66):41\u20138. https:\/\/doi.org\/10.1212\/01.wnl.0000191307.69661.c3.","journal-title":"Neurology"},{"issue":"8","key":"6065_CR52","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1212\/WNL.0000000000004264","volume":"89","author":"R Smith","year":"2017","unstructured":"Smith R, Sch\u00f6ll M, Widner H, et al. In vivo retention of 18F-AV-1451 in corticobasal syndrome. Neurology. 2017;89(8):845\u201353. https:\/\/doi.org\/10.1212\/WNL.0000000000004264.","journal-title":"Neurology"},{"key":"6065_CR53","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00401-016-1640-3","volume":"132","author":"CT McMillan","year":"2016","unstructured":"McMillan CT, Irwin DJ, Nasrallah I, et al. Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132:935\u20137. https:\/\/doi.org\/10.1007\/s00401-016-1640-3.","journal-title":"Acta Neuropathol"},{"key":"6065_CR54","doi-asserted-by":"publisher","unstructured":"Tezuka T, Takahata K, Seki M, et al Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. Brain Commun. 2021;3(4):fcab190. https:\/\/doi.org\/10.1093\/braincomms\/fcab190.","DOI":"10.1093\/braincomms\/fcab190"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06065-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-06065-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06065-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:44:01Z","timestamp":1679359441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-06065-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["6065"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-06065-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"assertion":[{"value":"25 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2\u00a0years, he has received consultancy\/speaker fees from Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Fujirebio, Genentech, Novartis, Roche, and Siemens. MH and SM are employees of F. Hoffmann-La Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}